ONWARD Medical Achieves Noteworthy Milestones in Q3 2025
EINDHOVEN, the Netherlands — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY) is proud to announce its significant advancement in the neurotechnology sector as it continues to introduce revolutionary therapies aimed at restoring movement and independence for individuals with spinal cord injuries (SCI). This report highlights the company's ongoing journey through the third quarter of 2025, showcasing commercial success, breakthrough regulatory approvals, and significant scientific contributions.
Commercial Success of ARC-EX Systems
The commercial landscape for ONWARD Medical has grown remarkably, with a target achievement of 40 ARC-EX Systems sold in Q3. This progress underscores the company’s commitment to providing advanced spinal cord stimulation technology designed to foster recovery for patients.
As of now, ARC-EX Therapy is available in over 60 clinics across the United States, allowing countless patients access to this innovative treatment.
Expanding Accessibility with Home Use
Recent regulatory achievements have paved the way for even broader accessibility of the ARC-EX System. The Company has secured CE Mark certification for the ARC-EX System, enabling both clinical and home use throughout the European Union. This certification not only allows for commercialization at home but also streamlines the regulatory process in other regions, such as the UK and Switzerland.
The US FDA has also granted 510(k) clearance for the ARC-EX System, marking it as the first technology approved to enhance hand strength and sensation in individuals with SCI.
Regulatory Milestones and Scientific Advances
ONWARD Medical has also reached critical regulatory milestones this quarter, with the FDA approving an investigational device exemption (IDE) for the ARC-IM System, which allows for the launch of the Empower BP pivotal study. This study aims to assess this innovative platform designed to combat blood pressure instability following spinal cord injuries.
Additionally, recent publications in notable scientific journals, including Nature and Nature Medicine, bolster the credibility of the Company’s therapies. These publications contribute vital evidence regarding the effectiveness of their innovative approaches, particularly in blood pressure management post-SCI.
Financial Performance
In terms of financial performance, ONWARD Medical reported an impressive EUR 1.7 million in revenue for Q3, marking its first time surpassing the EUR 1 million milestone in a single quarter. Moreover, a substantial equity capital raise of over EUR 50 million was completed in October, which is expected to secure the company’s operational resources into the first quarter of 2027.
Market Forecast and Future Directions
The positive user feedback and increasing demand for the ARC-EX System signal that ONWARD Medical is on a robust trajectory heading into its first year as a thriving commercial entity. With FDA and CE Mark clearances, the Company is well-positioned to accelerate growth in the upcoming year while strategically expanding the Empower BP clinical study.
Looking ahead, ONWARD plans to enhance its portfolio further with anticipated patient enrollment in its pivotal study and additional development of ARC-IM and ARC-BCI Systems to explore various new indications such as mobility improvements in SCI and Parkinson’s disease.
Engagement and Information Channels
ONWARD Medical is dedicated to keeping the community informed about their latest advancements and opportunities. The firm is set to host a webcast for interested parties, where CEO Dave Marver will discuss the insights from this quarter and future directions.
About ONWARD Medical
ONWARD Medical is a trailblazer in neurotechnology, committed to designing therapies that restore movement, independence, and functionality in individuals with spinal cord injuries and other mobility disabilities. Grounded in extensive research and clinical studies from leading medical facilities, the Company has created innovative solutions such as the ARC-EX System, which had previously received Breakthrough Device Designations from the FDA.
With their headquarters in the Netherlands and additional facilities in both Switzerland and the United States, ONWARD is positioned to make a considerable impact on the neurotechnology landscape. They remain committed to pushing the boundaries further and addressing the unmet needs of patients with spinal cord injuries.
Frequently Asked Questions
What is the purpose of the ARC-EX System?
The ARC-EX System is designed to deliver programmed spinal cord stimulation to improve hand sensation and strength in patients with spinal cord injuries.
How does ONWARD Medical plan to sustain growth?
By expanding its product offerings, securing regulatory approvals, and receiving positive user feedback, ONWARD Medical aims to maintain robust growth in the coming years.
Where can I find more information on ONWARD Medical's products?
For additional information, interested individuals can visit ONWARD Medical's official website.
What is the significance of the CE Mark certification?
CE Mark certification allows ONWARD Medical to commercialize its products within the European Union, facilitating access to therapy for patients in that region.
What are future indications ONWARD Medical is exploring?
ONWARD Medical is exploring additional indications such as mobility enhancement in SCI and Parkinson's disease through their advanced therapy systems.
